Results 71 to 80 of about 20,887 (223)

KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

Journal of Experimental & Clinical Cancer Research
Background Neuroblastoma (NB) patients with amplified MYCN often face a grim prognosis and are resistant to existing therapies, yet MYCN protein is considered undruggable.
Yi Yang, Yingwen Zhang, Guoyu Chen, Bowen Sun, Fei Luo, Yijin Gao, Haizhong Feng, Yanxin Li   +7 more
doaj   +1 more source

The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression

Journal of Experimental & Clinical Cancer Research, 2020
Background The oncogene MYCN is critical for tumorigenesis of several types of cancers including neuroblastoma. We previously reported that miR-506-3p repressed MYCN expression in neuroblastoma cells. However, the mechanism underlying such regulation was
Zhenze Zhao, Spencer D. Shelton, Alejandro Oviedo, Amy L. Baker, Collin P. Bryant, Soroush Omidvarnia, Liqin Du   +6 more
doaj   +1 more source

Network based approach identifies miR‐145‐3p as a central regulatory hub associated to the progression from localized to metastatic medullary thyroid carcinoma

The Journal of Pathology, EarlyView.
Abstract Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor originating from calcitonin producing C‐cells and accounts for 1–5% of thyroid cancers. Total thyroidectomy is curative in localized disease (N0), whereas lymph node metastases (N1) are associated with poorer prognosis.
Anna Citarella, Manuela Petti, Zein Mersini Besharat, Caterina Alfano, Elena Splendiani, Sofia Trocchianesi, Sara Cassandro, Martina Chiacchiarini, Claudia Sabato, Francesca Gianno, Tanja Milena Autilio, Martina Brunetti, Giuseppina Catanzaro, Antonella Verrienti, Rossella Elisei, Raffaele Ciampi, Cristina Romei, Maria Grazia Castagna, Silvia Cantara, Vincenzo Marotta, Luciano Pezzullo, Lorenzo Farina, Cosimo Durante, Agnese Po, Elisabetta Ferretti   +24 more
wiley   +1 more source

Letting the breaks off MYCN

, 2016
Much of our understanding of the biology of MYCN amplification in neuroblastoma is based on the exploration of transcriptional activity of MYCN.
MILAZZO, GIORGIO, Narayan, Nisha, PERINI, GIOVANNI, Paul G Ekert, Ekert, Paul G., Giorgio Milazzo, Nisha Narayan, Giovanni Perini   +7 more
core   +1 more source

MYCN-DNA-Vakzine zur Behandlung des Neuroblastoms [PDF]

, 2014
Das Neuroblastom (NB) zählt zu den therapieresistentesten Tumoren des Kleinkindalters. Besonders NB-Patienten mit MYCN-Amplifikation sind mit einer schlechten Prognose konfrontiert.
Stermann, Alexander
core   +1 more source

Interventional oncology in children: Where are we now?

Journal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel, Fernando Gómez Muñoz   +1 more
wiley   +1 more source

A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence [PDF]

Journal of Clinical Investigation, 2017
The most frequent focal alterations in human retinoblastoma are mutations in the tumor-suppressor gene retinoblastoma (RB) and amplification of the oncogene MYCN. Whether MYCN overexpression drives retinoblastoma has not been assessed in model systems. Here, we have shown that Rb inactivation collaborates strongly with MYCN overexpression and leads to ...
Nan, Wu, Deshui, Jia, Breanna, Bates, Ryan, Basom, Charles G, Eberhart, David, MacPherson   +5 more
openaire   +2 more sources

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN -amplified neuroblastoma

Science Advances, 2023
MYCN amplification ( MNA ) is a defining feature of high-risk neuroblastoma (NB) and predicts poor prognosis. However, whether genes within or in close proximity to the MYCN amplicon also contribute to MNA + NB ...
Hai-Feng Zhang, Alberto Delaidelli, Sumreen Javed, Busra Turgu, Taylor Morrison, Christopher S. Hughes, Xiaqiu Yang, Manideep Pachva, Michael M. Lizardo, Gurdeep Singh, Jennifer Hoffmann, Yue Zhou Huang, Khushbu Patel, Rawan Shraim, Sonia H. Y. Kung, Gregg B. Morin, Samuel Aparicio, Daniel Martinez, John M. Maris, Kristopher R. Bosse, Karla C. Williams, Poul H. Sorensen   +21 more
openaire   +2 more sources

Transcriptional regulation of genes by MYCN in PAX3::FOXO1-positive rhabdomyosarcomas and their roles in cell cycle progression

EJC Paediatric Oncology
Background: MYCN amplification and high expression is associated with pediatric malignancies including neuroblastoma and alveolar rhabdomyosarcoma. MYCN transcription in alveolar rhabdomyosarcomas is driven by a feedback loop with the PAX3::FOXO1 fusion ...
Zoë S. Walters, Daniel Leongamornlert, Barbara Villarejo-Balcells, Carmen Tse, Reuben Pengelly, Ian Titley, Janet Shipley   +6 more
doaj   +1 more source

AOSNP‐ADAPTR resource level‐based recommendations on practical diagnostic strategies for ependymomas

Brain Pathology, EarlyView.
Adapting Diagnostic Approaches for Practical Taxonomy in Resource‐Restrained Regions (ADAPTR) recommendations for ependymomas in resource‐restrained settings (RL = resource level; created in BioRender). Abstract Ependymomas are uncommon primary tumors of the central nervous system (CNS) that affect both children and adults.
Laveniya Satgunaseelan, Michael E. Buckland, Geeta Chacko, Kenta Masui, Junji Shibahara, Vani Santosh, Maysa Al‐Hussaini, Sung‐Hye Park, Tarik Tihan, Ho‐Keung Ng, Pieter Wesseling, David N. Louis, Chitra Sarkar, Takashi Komori   +13 more
wiley   +1 more source